EcoDrugPlus

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSSTUG00000048683
Gene Symbol: CHRNB2
1 Cross references
196 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSSTUG00000040494
Gene Symbol: CHRNB4
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSSTUG00000037389
Gene Symbol: CHRM2A
1 Cross references
189 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSSTUG00000010507
Gene Symbol: F2R
3 Cross references
257 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSSTUG00000038465
Gene Symbol: F2R
3 Cross references
257 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSSTUG00000046110
Gene Symbol: F2R
3 Cross references
216 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSSTUG00000049389
Gene Symbol: F3
3 Cross references
172 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSSTUG00000005084
Gene Symbol: F3A
1 Cross references
190 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSSTUG00000009634
Gene Symbol: LOC115196382
3 Cross references
78 Possible Orthologues:

Coagulation Factor X-Like

Ensembl ID : ENSSTUG00000049047
Gene Symbol: LOC115179127
3 Cross references
236 Possible Orthologues:

Coiled-Coil Domain-Containing Protein 6-Like

Ensembl ID : ENSSTUG00000025219
Gene Symbol: LOC115193678
3 Cross references
201 Possible Orthologues:

Coiled-Coil Domain-Containing Protein 6-Like

Ensembl ID : ENSSTUG00000048047
Gene Symbol: LOC115153281
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).